Innovent Biologics shares surged 10% after announcing a landmark oncology partnership with Pfizer, potentially worth up to $10.5 billion. The deal involves licensing, co-development, and co-commercialization of 12 early-stage cancer medicines, including antibody-drug conjugates. Innovent will receive $650 million upfront, retain Greater China rights, and co-commercialize in the U.S. and Europe, highlighting a strategic move to address global oncology needs.
READ MORE FROM CNBC
Shares of Innovent Biologics surged by an impressive 10% following the announcement of a groundbreaking collaboration with pharmaceutical giant Pfizer. This monumental agreement, valued at up to $10.5 billion, is set to revolutionize the development of oncology medicines.
The comprehensive partnership encompasses licensing, co-development, and co-commercialization opportunities across an extensive portfolio of antibody-drug conjugates. This ambitious initiative will see both companies embark on the research and development of 12 pioneering early-stage and de novo cancer treatments, as detailed in Innovent's official filing.
Two employees in pharmaceutical industry wearing protective gloves, mask, cap and white suit seen standing by the machine that is the part of the medicaments production during the working hours in a pharmaceutical manufacturing.
Credit: Extreme-photographer | E+ | Getty ImagesUnder the terms of the deal, Innovent will spearhead the development of four global programs in conjunction with Pfizer, sharing the associated costs. Furthermore, the Hong Kong-listed biotech firm will engage in co-commercialization efforts with Pfizer across the crucial U.S. and European markets, sharing in the profits generated. Importantly, Innovent will maintain exclusive rights to these programs within the lucrative Greater China market.
Financially, Innovent is slated to receive a substantial upfront payment of $650 million. Beyond this initial sum, the company stands to gain up to an additional $9.85 billion in development, regulatory, and commercial milestone payments. This brings the potential total value of the collaboration to an astounding $10.5 billion. "Additionally, Innovent will receive up to double-digit royalties on sales of each product if approved," the company confirmed, emphasizing that the transaction's closing is contingent upon obtaining necessary regulatory approvals.
This strategic alliance underscores a growing trend in the pharmaceutical industry, where partnerships between innovative biotech firms and established pharmaceutical giants are increasingly vital. Such collaborations are particularly focused on addressing the escalating global concern over oncology-related diseases. Industry analysts, like those at Gibson Dunn, highlight that "Large pharmaceutical companies, in particular, utilized licensing as a surgical tool to address near-term pipeline gaps ahead of the '2026–2030 patent cliff'." This deal positions both Innovent and Pfizer strongly in the competitive landscape of cancer treatment development.
Following the news, Innovent's shares saw a robust gain, closing up 6.41% at HK$79.65.
